## Monthly Factsheet | 31 AUGUST 2024

For professional and accredited investors only. Not for further distribution. Marketing communication. Refer to the Fund prospectus, KID/KIID and/or offering documents before making investment decisions.

## WELLINGTON MANAGEMENT®

# Wellington Global Health Care Equity Fund

## EUR S Accumulating Hedged

#### SUMMARY RISK INDICATOR



Capital at risk: please refer to the bottom of this page for details about the Summary Risk Indicator.

### **FUND DETAILS**

Fund Inception: November 2000 Share Class Inception: February 2017 Fund Assets: USD 2.6 billion NAV: EUR 15.94 Currency Hedging Type: NAV Hedged

## **KEY INFORMATION**

#### Domicile: Ireland Regulatory Regime: UCITS Legal Structure: Public Limited Company Dealing Frequency: Daily Country Registration: Ireland, Portugal, Singapore \*, Spain, Switzerland. ISIN: IEO0BYQ44T06 \*Restricted scheme

## FUND CHARACTERISTICS

Asset-Weighted Market Capitalisation:	USD 225.5 billion
Beta (3 Yr):	0.99
Tracking Risk (3 Yr, Annualised):	5.6%
Turnover:	44.0%

## FEES AND PRICING

Minimum Investment: USD 1 million Management Fee: 1.25% p.a.

Ongoing Charges Figure \*: 1.33%

\*The ongoing charges figure excludes Fund transaction costs, except in the case of depositary fees and an entry/exit charge paid by the Fund when buying or selling Shares in another collective investment undertaking. A detailed description of the charges that apply is set out in the section "Charges and Expenses" in the Prospectus. The ongoing charges figure may change over time. Charges applied will reduce the return potential of investments. | If an investor's own currency is different from the currency shown, costs could increase or decrease due to currency or exchange related fluctuations.

For more information, please visit **www.wellingtonfunds.com** 

## SUMMARY OF INVESTMENT OBJECTIVE AND POLICY

The Wellington Global Health Care Equity Fund seeks long-term total returns in excess of the MSCI World Health Care Index. The Investment Manager will actively manage the Fund, seeking to achieve the objective by investing in the equity securities of health care companies worldwide. The Fund takes a long term value approach and seeks to invest in fundamentally sound companies.


#### **FUND PERFORMANCE (%)**

Past performance does not predict future returns.

#### TOTAL RETURNS NET OF FEES AND EXPENSES

	YTD	1 MO	3 MOS	1 YR	3 YRS	5 YRS	10 YRS	SINCE INCEPTION
EUR S Acc Hdg	14.4	5.1	10.7	18.4	-0.8	7.9	-	6.4
MSCI World Health Care USD NAV Hedged EUR Net Dividends	16.3	5.2	10.4	18.0	3.1	9.8	-	8.6

#### CALENDAR YEAR RETURNS



#### DISCRETE ANNUAL PERFORMANCE

									SEP '15 - AUG '16	
EUR S Acc Hdg	18.4	3.6	-20.3	15.3	29.8	-10.5	12.2	-	-	-
MSCI World Health Care USD NAV Hedged EUR Net Dividends	18.0	6.7	-13.0	22.1	19.5	-3.0	10.3	-	-	-

#### Past results are not necessarily indicative of future results and an investment can lose value.

The inception date of the EUR S Acc Hdg share class is 17 February 2017. | Periods greater than one year are annualised. | If an investor's own currency is different from the currency in which the fund is denominated. the investment return may increase or decrease as a result of currency fluctuations. | Fund returns shown are net of EUR S Acc Hdg share class fees. Fund returns shown are net of fUR S Acc Hdg share class fees. Fund returns shown are net of fuR adjusted for the effects of taxation and assume reinvestment of dividends and capital gains. The index returns, where applicable, are shown net of maximum withholding and assume reinvestment of dividends. | Please note the fund has a swing pricing mechanism in place. Index - MSCI. | If the last business day of the month is not a business day for the Fund, performance is calculated using the last available NAV. This may result in a performance differential between the fund and the index. | Source: Fund - Wellington Management.

## FUND MANAGEMENT

## **Re** 19

Rebecca Sykes, CFA 19 years of experience

Wellington Management Company LLP (WMC) is an independently owned investment adviser registered with the US Securities and Exchange Commission. WMC, along with its affiliates (collectively, Wellington Management), provides investment and investment advisory services to institutions around the world. This material and its contents may not be reproduced or distributed, in whole or in part, without the express written consent of Wellington Management. Nothing in this document should be interpreted as advice, nor is it a recommendation to buy or sell shares in Wellington Management Funds (Ireland) plc (the Fund. Investment in the Fund may not be suitable for all investors. Fund shares are made available only in jurisdictions where such offer or solicitation is lawful. Please read the latest Key Information Document (KID), Prospectus, and latest annual report) faore investing. For each country where the Fund is registered for sale, the prospectus, complaints procedure and summary of investor rights in English, and the KID in English and an official language (for Belgium: Dutch, French and German), are available fore of charge from the Funds Transfer Agent State Street Fund Services (Ireland) Limited, 78 Sir John Rogerson's Quay, Dublin 2, Ireland and from https://sites.wellington.com/KIIDS\_wmf/Countries/belgium.html. Complaints can be submitted to the Complaints Officer at the address of the Funds Transfer Agent or by email to WellingtonGlobalTA@statestreet.com. The Fund savenees to shares in an EU Member State by giving 30 working days' notice. I In Switzerland, the Fund Offering documents can be obtained from the local Representative and Paying Agent, BNP Paribas Securities Services, Selnaustrasse 16, 8002 Zurich, Switzerland. The Prospectuses are available in English. | Summary Risk Indicator: based on a combination of market and credit risk measures. Historical data may not be a reliable indication for the future. Risk category shown is not guaranteed and may shift over time. The lowest category does not mean 'r

## Monthly Factsheet Wellington Global Health Care Equity Fund | EUR S Accumulating Hedged

#### WHAT ARE THE RISKS?

CAPITAL: Investment markets are subject to economic, regulatory, market sentiment and political risks. All investors should consider the risks that may impact their capital, before investing. The value of your investment may become worth more or less than at the time of the original investment. The Fund may experience a high volatility from time to time.

CONCENTRATION: Concentration of investments within securities, sectors or industries, or geographical regions may impact performance.

CURRENCY: The value of the Fund may be affected by changes in currency exchange rates. Unhedged currency risk may subject the Fund to significant volatility.

EQUITIES: Investments may be volatile and may fluctuate according to market conditions, the performance of individual companies and that of the broader equity market.

**HEDGING:** Any hedging strategy using derivatives may not achieve a perfect hedge.


MANAGER: Investment performance depends on the investment management team and their investment strategies. If the strategies do not perform as expected, if opportunities to implement them do not arise, or if the team does not implement its investment strategies successfully; then a fund may underperform or experience losses.

SMALL AND MID-CAP COMPANY: Small and mid-cap companies' valuations may be more volatile than those of large cap companies. They may also be less liquid.


SUSTAINABILITY: A Sustainability Risk can be defined as an environmental, social or governance event or condition that, if it occurs, could cause an actual or potential material negative impact on the value of an investment.

Before subscribing, please refer to the Fund offering documents/prospectus for further risk factors and pre-investment disclosures. For the latest NAV, please visit www.fundinfo.com.

#### **REGIONAL DISTRIBUTION**







Totals may not add up to 100% due to rounding.

#### **TOP 10 HOLDINGS**

COMPANY NAME	MARKET	INDUSTRY	% OF EQUITY
Eli Lilly & Co	United States	Pharma, Biotech & Life Sciences	9.1
UnitedHealth Group	United States	Health Care Equipment & Services	7.1
Novo Nordisk A/S	Denmark	Pharma, Biotech & Life Sciences	5.4
AstraZeneca PLC	United Kingdom	Pharma, Biotech & Life Sciences	4.4
Merck & Co	United States	Pharma, Biotech & Life Sciences	4.1
Novartis AG	Switzerland	Pharma, Biotech & Life Sciences	2.8
Danaher Corp	United States	Pharma, Biotech & Life Sciences	2.7
Boston Scientific	United States	Health Care Equipment & Services	2.5
Intuitive Surgical	United States	Health Care Equipment & Services	2.2
Argenx SE	Belgium	Pharma, Biotech & Life Sciences	2.2
Total of Top 10			42.5
Number of Equity Names			99

The individual issuers listed should not be considered a recommendation to buy or sell. The weightings do not reflect exposure gained through the use of derivatives. Holdings vary and there is no guarantee that the Fund currently holds any of the securities listed. Please refer to the annual and semi-annual report for the full holdings.

In the following countries, this material is provided by: Canada: Wellington Management Canada ULC, a British Columbia unlimited liability company registered in the provinces of Alberta, British Columbia, Manitoba, New Brunswick, Newfoundland and Labrador, Nova Scotia, Ontario. Prince Edward Island, Quebec, and Saskatchewan in the categories of Portfolio Manager and Exempt Market Dealer. UK: Wellington Management International Limited (WML), authorised and regulated by the Financial Conduct Authority (Reference number: 208573). Europe (ex. UK and Switzerland): marketing entity Wellington Management Europe GmbH which is authorised and regulated by the German Federal Financial Services Authority ("DFA"). To the extent this document relate or any vay to German relation rampices for Wellington Management IUFC) Limited (WM DIFC), a time registered in the DIFC with number 7181 and regulated by the Dubai Financial Services Authority ("DFA"). To the extent this document relates any steps to verify the information sector approval by the DFS A has no responsibility for rejueixing or verifying any prospectus or other documents in connection with any financial product to which this document nay tepts to verify the information set out in this document, and has no responsibility for it. Any financial product to which this document relates may be elliquid and/or subject to restrictions on its resale. Prospective purchasers should conduct their own due diligence on any such financial product. If you do not understand the contents of this document you should consult an authorised financial adviser. This document (WM Hong Kong). A corporation licensed by the Securities and Futures Commission to conduct type 2 (dealing in futures contracts). Type 4 (davising on securities), and type 9 (Registration Number 2010 for MAI), prove dent securities and periode futures Commission to conduct type 1 (dealing in securities). Type 2 (dealing in futures contracts). Type 4 (davising on securities), and prove 9 (Registration Number 2010 for MAI